Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
 LLY | Eli Lilly & Co. | $1.0t | $1211.50 | +7.4% | 5.3M |
 RVMD | Revolution Medicines, Inc. Common Stock | $33.5b | $182.99 | +2.2% | 2.9M |
 INCY | Incyte Genomics Inc | $19.3b | $112.75 | +5.8% | 2.2M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $14.8b | $229.94 | +1.7% | 517.2K |
 EXEL | Exelixis Inc | $12.7b | $54.90 | +3.0% | 1.8M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $8.7b | $123.85 | -0.0% | 1.6M |
 HALO | Halozyme Therapeutics, Inc. | $7.9b | $75.08 | +3.2% | 1.7M |
 CORT | Corcept Therapeutics Inc. | $7.5b | $86.66 | +3.1% | 616.3K |
 CELC | Celcuity Inc. Common Stock | $6.5b | $99.14 | +4.2% | 1.2M |
 COGT | Cogent Biosciences, Inc. Common Stock | $6.0b | $38.20 | +0.0% | 3.1M |
 ERAS | Erasca, Inc. Common Stock | $4.0b | $16.05 | +6.9% | 7.7M |
 TNGX | Tango Therapeutics, Inc. | $3.2b | $30.50 | +4.3% | 6.0M |
 RLAY | Relay Therapeutics, Inc. Common Stock | $3.1b | $18.67 | +3.9% | 4.0M |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $2.6b | $35.44 | +1.2% | 1.7M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $2.5b | $50.07 | +2.0% | 3.3M |
 IMNM | Immunome, Inc. | $2.5b | $19.87 | +3.0% | 1.6M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 TYRA | Tyra Biosciences, Inc. Common Stock | $2.0b | $31.91 | +3.0% | 1.3M |
 NVCR | NovoCure Limited Ordinary Shares | $2.0b | $15.31 | +2.7% | 877.1K |
 ZYME | Zymeworks Inc. | $1.8b | $24.42 | +1.6% | 390.1K |
 NRIX | Nurix Therapeutics, Inc. Common stock | $1.8b | $22.35 | +2.0% | 2.9M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.7b | $22.23 | +2.9% | 1.6M |
 NUVB | Nuvation Bio Inc. | $1.7b | $5.62 | -3.3% | 26.5M |
 BHVN | Biohaven Ltd. | $1.7b | $15.89 | +3.2% | 5.1M |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.6b | $10.18 | +2.0% | 2.0M |
 DMRA | Damora Therapeutics, Inc. Common Stock | $1.5b | $25.43 | +11.9% | 1.4M |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.4b | $33.98 | +0.5% | 610.9K |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $1.4b | $34.55 | +0.4% | 378.5K |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.2b | $11.03 | -0.5% | 2.8M |
 KURA | Kura Oncology, Inc. | $0.9b | $10.98 | +5.1% | 1.5M |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $0.9b | $9.21 | +0.7% | 1.2M |
 GERN | Geron Corp | $0.8b | $1.31 | -3.6% | 24.9M |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.8b | $6.68 | +3.1% | 2.4M |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.7b | $7.41 | -3.3% | 650.1K |
 ARVN | Arvinas, Inc | $0.6b | $7.89 | 0.0% | 934.5K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.6b | $38.19 | +4.4% | 188.9K |
 STRO | Sutro Biopharma, Inc. | $484.4m | $30.55 | +3.2% | 373.6K |
 CCCC | C4 Therapeutics, Inc. | $483.2m | $4.39 | -0.2% | 6.3M |
 MNPR | Monopar Therapeutics Inc. Common Stock | $435.7m | $87.56 | +0.0% | 166.3K |
 ADCT | ADC Therapeutics SA | $432.4m | $1.03 | -1.9% | 997.4K |
 VSTM | Verastem, Inc. | $380.5m | $3.77 | +9.6% | 3.7M |
 IMRX | Immuneering Corporation Class A Common Stock | $373.3m | $4.75 | +4.9% | 1.1M |
 DCTH | Delcath Systems Inc | $372.1m | $12.88 | +5.3% | 534.4K |
 PBYI | PUMA BIOTECHNOLOGY INC | $364.9m | $8.08 | +5.9% | 312.9K |
 PRLD | Prelude Therapeutics Incorporated | $312.2m | $4.22 | +6.7% | 408.2K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $284.7m | $4.04 | +7.1% | 1.5M |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $258.6m | $27.21 | -2.5% | 830.6K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $233.4m | $4.16 | +1.5% | 435.4K |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $209.4m | $4.79 | +7.4% | 445.9K |
 KPTI | Karyopharm Therapeutics Inc. | $206.2m | $10.15 | +7.6% | 494.7K |